Gallium 68 PNT 6555
Alternative Names: [Ga-68]-PNT-6555; Gallium-68-PNT-6555Latest Information Update: 01 Jan 2024
At a glance
- Originator Tufts University School of Medicine
- Developer POINT Biopharma
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 27 Dec 2023 POINT Biopharma has been acquired by Eli Lilly and Company
- 29 Nov 2022 Pharmacodynamics data from a preclinical trial in Solid tumours released by POINT Biopharma
- 13 Jul 2022 Phase-I clinical trials in Solid tumours (In adults, In the elderly, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT05432193)